Effectiveness of local anticoagulation of the ECMO oxygenator during flow reduction trial in patients on V-A ECMO: a prospective observational cohort study

Recruiting

• Conditions: Cardiogenic shock; 10019280

• Registration Number: NL-OMON54247
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 16

Inclusion Criteria

All adult (>18 years old) patients on V-A ECMO with a planned flow reduction
trial can be included in this study.

Exclusion Criteria

- Patients in whom a heparin bolus has be given due to low APTT just prior to a
planned flow reduction trial
- Patient with supratherapeutic APTT (>80ms)
- Flow reduction trial lasting less than 15 min
- No informed consent

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoint of the study is the increase in APTT in the ECMO circuit at<br /><br>the end of a flow reduction trial compared to the start of the flow reduction<br /><br>trial</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- The increase in systemic APTT after a flow reduction trial.<br /><br>- The increase in aXa and Inten CT- Heptem CT both in the ECMO circuit and<br /><br>systemic at the end of a flow reduction trial compared to the start of the flow<br /><br>reduction trial</p><br>